


Listing of the Claims

This listing of claims will replace all prior version, and listings, of claims in the application:

- 1) (Amended) A lipid compound represented by the formula



wherein R₁ is a long chain fatty acid, R₂ is a long chain fatty ~~chain-acid~~ between 11 and 25 carbons in length, and ~~wherein the variable "n" is an integer between 11 and 46~~, and

wherein said compound is characterized by the ability to inhibit biological activity of phospholipase A₂.

- 2) CANCEL

- 3) (Original) The compound of claim 1, wherein said compound is characterized by the ability to inhibit biological activity of cyclooxygenase-2

- 4) (Original) The compound of claim 1, wherein said R1 long chain fatty acid is between 11 and 25 carbons in length.

- 5) (Original) The compound of claim 1, wherein said R2 long chain fatty acid is between 11 and 25 carbons in length.

6) (Original) The compound of claim 1, wherein the variable “n” is an integer between 11 and 46.

7) (Amended) The compound of claim 1, wherein R1 represents a long chain fatty acid selected from the group consisting of:

- (a) $\text{CH}_3(\text{CH}_2)_{10}$,
- (b) $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$, and
- (c) $\text{CH}_3(\text{CH}_2)_{12-13}$
- (d) $\text{CH}_3(\text{CH}_2)_{14}$, and
- (e) $\text{CH}_3(\text{CH}_2)_{16-17}$

8) (Original) The compound of claim 1, wherein R2 represents a long chain fatty acid selected from the group consisting of:


- (a) $\text{CH}_3(\text{CH}_2)_{10}$,
- (b) $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$,
- (c) $\text{CH}_3(\text{CH}_2)_{12}$,
- (d) $\text{CH}_3(\text{CH}_2)_{14}$, and
- (e) $\text{CH}_3(\text{CH}_2)_{16}$.

9) (Original) The compound of claim 1, wherein the variable “n” is an integer between 11 and 46, and wherein R1 and R2 each represent a long chain fatty acid selected from the group consisting of:

- (a) $\text{CH}_3(\text{CH}_2)_{10}$,
- (b) $\text{CH}_3(\text{CH}_2)_{10}(\text{CH})_2(\text{CH}_2)_7$,
- (c) $\text{CH}_3(\text{CH}_2)_{12}$,
- (d) $\text{CH}_3(\text{CH}_2)_{14}$, and
- (e) $\text{CH}_3(\text{CH}_2)_{16}$.

10) CANCEL

- 11) CANCEL
- 12) CANCEL
- 13) CANCEL
- 14) CANCEL
- 15) CANCEL
- 16) CANCEL
- 17) CANCEL
- 18) CANCEL
- 19) CANCEL
- 20) CANCEL
- 21) CANCEL
- 22) (Amended) A composition of matter comprising one or more lipids having the formula



wherein R₁ is a long chain fatty acid ~~chain between 11 and 25 carbons in length~~, R₂ is a long chain fatty ~~acid chain between 11 and 25 carbons in length~~, and wherein the variable “n” is an integer ~~between 11 and 46~~, and

wherein said compound is further characterized by the ability to inhibit biological activity of ~~phospholipase A₂~~ cyclooxygenase-2.

23) CANCEL

24) CANCEL

25) (Amended) The composition of matter of claim ~~22~~1, wherein said composition is a pharmaceutical composition

26) (Original) The composition of matter of claim 25, further comprising a pharmaceutically acceptable carrier.

27) (Amended) The composition of matter of claim ~~22~~1, wherein said composition is a foodstuff.

28) (Amended) The composition of matter of claim ~~22~~1, wherein said composition is a dietary supplement.

29) (Amended) The composition of matter of claim ~~22~~1, wherein said composition is a cosmetic.

30) (Amended) The composition of matter of claim ~~26~~25, further comprising a delivery form selected from the group consisting of: a tablet, a capsule, a syrup, a dragee, a suspension, an elixer, a solution, a powder, granules, an emulsion, microspheres, nanospheres, lipid vesicles, polymeric vesicles, ~~or an injectable, an ointment, a cream, a milk, an impregnated pad, a gel, a spray, and a lotion.~~

31) CANCEL

32) CANCEL

33) CANCEL

34) CANCEL

35) CANCEL

36) CANCEL

37) CANCEL

38) CANCEL

39) CANCEL

40) (Amended) A method for treating an inflammation related condition in a mammal comprising the step of administering a composition according to claim ~~28~~25.

41) (Amended) A method for treating an inflammation related condition in a mammal comprising the step of administering a composition according to claim ~~29~~28.


42) CANCEL

43) CANCEL

44) CANCEL

45) CANCEL

46) (Amended) A method for treating an inflammation related condition in a mammal comprising the step of administering an effective amount of a composition of matter comprising one or more lipids having the formula



Wherein R₁ is a long chain fatty acid ~~between 11 and 25 carbons in length~~, R₂ is a long chain fatty acid ~~between 11 and 25 carbons in length~~, and wherein the variable “n” is an integer between 11 and 46.

47) (Amended) The method of claim 46, wherein said composition of matter is a pharmaceutical composition ~~further comprising a pharmaceutically acceptable carrier.~~

48) (Original) The method of claim 46, wherein said composition of matter is a foodstuff.

49) (Original) The method of claim 46, wherein said composition of matter is a dietary supplement.

50) (Original) The method of claim 46, wherein said composition of matter is a cosmetic.

51) CANCEL

52) CANCEL

53) CANCEL

54) CANCEL

55) CANCEL

56) CANCEL

57) CANCEL

58) CANCEL

59) CANCEL

60) CANCEL